Therapeutic success by specific biologics points to the pathogenic role of the tumor necrosis factor-α (TNF-α) axis and the interleukin (IL)-23/IL-17A axis in psoriasis [8,9,10,11,12,13]. This evidence concerns the gene IL17A and psoriasis.